Palmetto GBA, a national contractor that administers Medicare benefits, issued a positive coverage policy through the MolDX Program for the Decipher prostate cancer classifier developed by GenomeDx Biosciences.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
